Manhattan Associates Inc vs GeneDx Holdings Corp — how do they compare? Manhattan Associates Inc trades at $192.8 (market cap $11.38B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: Manhattan Associates Inc is far larger — about 4.7× GeneDx Holdings Corp's market cap, and Manhattan Associates Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| MANH | WGS | |
|---|---|---|
Market Cap | $11.38B | $2.44B |
Sector | Technology | Technology |
52-Week High | $220.19 | $167.51 |
52-Week Low | $120.88 | $34.51 |
Enterprise Value | $11.25B | $2.48B |
Signals from Pluang's Aura AI — not financial advice
MANH trades at $191.05, down 2.37% on the day, but maintains a bullish technical outlook with strong moving average signals and support near $192. The company reported robust Q2 2026 earnings, beating EPS estimates with $1.39 versus $1.32 expected, driven by 26% cloud revenue growth. However, a legal investigation into fiduciary duties by Rosen Law Firm presents a headwind. Analyst consensus remains strongly bullish with a $210.33 price target and 80% buy ratings.
The stock offers upside potential from consistent earnings beats and cloud momentum, but faces risks from the ongoing legal probe and elevated valuation multiples. Net income is projected to dip slightly in 2026, necessitating careful monitoring of execution against guidance. The current price sits just above key support, with resistance at $199.
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
Trailing returns across standard periods
Latest headlines on both assets
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →